Marine product off Florida’s coast might help fight cancer

March 5, 2021

From cyanobacteria blooms found off the Florida coast near Fort Lauderdale, University of Florida researchers have discovered a novel marine natural product that binds to a new site of tubulin, an important target for cancer drugs, according to a news release from the university.

Tubulin is a group of proteins found in the cytoplasm of cells, outside the nucleus. They serve as building blocks of microtubules, which are involved in cellular structure and aid in cell division.

Natural products targeting tubulin have provided the basis for several anti-cancer drugs approved by the Food and Drug Administration, including paclitaxel and vincristine.

For decades, cancer researchers have explored new ways to modify the protein’s function and dynamics by developing compounds that target one of tubulin’s six binding sites. The UF researchers discovered a new chemical compound that targets a seventh binding site.

“Tubulin is among the most successfully targeted proteins related to cancer chemotherapy, and there is tremendous interest in discovering new molecules that bind to tubulin,” said Hendrik Luesch, PhD, Professor and Chair of Medicinal Chemistry and the Debbie and Sylvia DeSantis Chair in Natural Products Drug Discovery and Development in the UF College of Pharmacy and a member of UF Health Cancer Center.

Identifying and fully characterizing this new tubulin-targeting compound and binding site took years of work. The compound gatorbulin-1 pays tribute in name to the UF researchers and global partners who led the way to its discovery and characterization.

In a study published in the journal Proceedings of the National Academy of Sciences, Luesch and his research team report on gatorbulin-1’s chemical and biological development, including the isolation, structure determination and chemical synthesis of the new natural product.

Gatorbulin-1’s origins in the Atlantic Ocean add to a growing list of compounds Luesch’s team has discovered from marine natural products. The biodiversity present in the world’s oceans offers a wealth of opportunity for exploration of new drug therapies.

Luesch previously discovered the tubulin agent dolastatin 10 from another marine cyanobacteria, which served as the basis for the development of three FDA-approved antibody-drug conjugates targeting a different tubulin binding site.

Visit University of Florida for more news

Photo 88130778 © Nataliia Mysik |
Photo 186155390 © Noipornpan |
Photo 171358238 © Nataliia Mysik |
Photo 84222773 © 7active Studio |
Photo 43618677 © Anupong Thiprot |